Sage Journals: Discover world-class research

Abstract

Introduction:

Venous thromboembolism (VTE) is a multifactorial condition and one of the leading causes of mortality and disability. The present study explores the factors associated with hospitalization duration among different types of venous thromboembolism diagnoses, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and other forms of thrombosis.

Methods:

The data included participants with VTE admitted to 13 hospitals within pan-India from June 2022 to December 2023 to the i-RegVed registry, where socio-demographic data, clinical history, and various factors associated with hospital length of stay (LOS) were included for analyses. Multilinear regression was performed to explore the factors associated with hospital LOS among VTE conditions such as DVT, PE, forms of thrombosis other than PE and DVT, and all VTE diagnoses.

Results:

A total of 633 participants were included in the study, with 55% being males, and 28.9% being homemakers. Longer hospital LOS was significantly associated with age (β = −.09, P < .05), sex (β = 3.21, P < .05), and non-communicable diseases (β = 3.51, P < .05) among participants with DVT and among participants with at least one of the VTE diagnoses, age (β = −.12, P < .001) and anticoagulant use (β = −2.49, P < .05) was significantly associated.

Conclusion:

The findings provide insights into the factors influencing hospital outcomes among participants with different types of VTE, highlighting the importance of age and comorbidities in predicting the hospital LOS.

Keywords

venous thromboembolism hospital length of stay i-RegVed India

Introduction

Venous thromboembolism (VTE) is a multifactorial condition that primarily includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Still, thrombosis can affect other veins, including upper extremities, cerebral venous sinuses, and splanchnic veins, and is estimated to be the third most frequent cardiovascular mortality in Western countries.¹ In Asian countries, the disease burden of VTE has always been considered lower.² However, the incidence rates of VTE are increasing,^3
-5 making it a major health concern in many Asian countries, including India.⁶

The earliest known case of VTE was reported in the right leg of a 20-year-old man in the 13th century.⁷ Several hypotheses to understand the mechanism of VTE have been postulated,^8,9 of which Virchow’s triad is often discussed and provides the basis for thrombosis-related research today. Virchow’s triad describes hypercoagulability, stasis, and endothelial injury as factors contributing to the development of venous thrombosis.¹⁰ However, it does not fully explain the increased risk of recurrent VTE and the need for an extended duration of anticoagulant use, and the underlying mechanism leading to the reoccurrence remains unclear.¹¹

The clinical presentation of DVT varies with the location and extent of occlusion of the thrombus.¹² Common symptoms include swelling and pain in the lower extremities, blue-red or cyanotic discoloration, tenderness, and thermoregulatory changes such as increased temperature.^13,14 DVT also varies between provoked and unprovoked. As such, provoked DVTs result from risk factors such as surgery and injury, however unprovoked DVT occurs without any apparent risk factors.¹⁵ On the other hand, PE is associated with dyspnea, chest pain, cough, hemoptysis, and hemodynamic instability in the form of hypotension and hypoxia.^14,16 Although the symptoms are common in most VTE patients, all do not experience these symptoms, making it difficult for earlier VTE diagnoses.

The risk factors of VTE include age, obesity, immobility, previous history of VTE, cancer, major trauma, autoimmune diseases, chemotherapy, hormone replacement therapy, postpartum period, long-haul travel, major surgery, blood transfusions, smoking, diabetes, genetics, and medications such as antipsychotics, antidepressants, diuretics, or analgestics.^16
-28 Studies have also noted that after the initial occurrence of VTE among unprovoked patients, they remain at a higher risk of developing recurrent thrombosis.^29,30 Notably, there is an increased risk of medical complications and functional decline with longer hospital lengths of stay (LOS), which in turn, may increase the risk of VTE.³¹ For instance, a population-based study in Norway on 530 cancer-free VTE patients indicated that hospitalization was a major trigger associated with a 9-fold higher risk of VTE, which was mainly dependent on the hospital LOS but not the frequency of hospital admissions.³²

In response to the growing incidences of hospital-acquired VTE as a preventable healthcare-associated complication, healthcare organizations have initiated targeted interventions and quality improvement initiatives. For example, the American Heart Association called to action in 2017 to reduce hospital-acquired VTE by 20% by the year 2030.³³ The National Institute for Health and Care Excellence (NICE) also published guidance for reducing the risk of hospital-acquired VTE.³⁴ The guideline includes recommendations such as risk assessment, giving information and planning for discharge, and interventions for different conditions (eg, renal impairment, cancer, major trauma, etc.) Despite these initiatives, data on the hospital LOS among VTE patients are limited,³⁵ causing a significant gap in understanding the factors influencing hospitalization among VTE patients in India. Moreover, the differences in hospital duration among other types of VTE such as Budd-Chiari are unavailable.

Given the complications of VTE associated with hospitalization,^36,37 there is a need for further research to elucidate the impact of hospitalization duration on the types of VTE. By highlighting factors that might prolong hospitalization among participants with different VTE types, healthcare providers can identify high-risk patients and help implement targeted interventions to mitigate adverse outcomes. Moreover, an improved understanding of the factors influencing hospital duration among different VTE types could help patients and their care providers reduce their elevated risks. The present study seeks to investigate the relationship between hospitalization duration and VTE types such as PE, DVT, PE and DVT, other single forms of thrombosis (eg, Budd-Chiari), and other multiple forms of thrombosis, focusing on identifying the determinants of hospital LOS.

Methods

Study Setting

This prospective hospital-based study was conducted across India from June 2022 to December 2023. Participating sites included 13 hospitals, where VTE patient data was collected with the help of a structured questionnaire, and data collected was uploaded to the National VTE Registry, the i-RegVeD registry.^38,39

Study Data Variables

Inclusion Criteria

All participants who experienced one or more events of objectively confirmed VTE, including other sites of venous thrombosis, through X-rays, CT scans, MRI, and/or ultrasound, were included in this study. Moreover, we included only those participants whose outcome was recovered and were discharged to observe the factors associated with the hospital LOS in our population. Thus, out of 1006 participants, 633 were included in this study (Figure 1).

Figure 1.

Flow chart showing participant selection.

Exclusion Criteria

Participants were excluded if they were diagnosed with arterial thrombosis and those with either missing hospital LOS or without VTE outcomes from diagnostic imaging were excluded. Moreover, we excluded participants who were either referred from a different hospital at the time of admission, referred from the hospital to another facility, left against medical advice, or died.

Data Collection

Data on age, sex, occupation, locality, family history of VTE, duration of hospital stays, medical procedures, and chronic diseases were included. Hospital LOS was calculated based on the date of admission to the hospital and the date of discharge from the hospital. The VTE status objectively confirmed through diagnostic techniques was divided into (a) DVT, (b) PE, (c) DVT with PE, (d) forms of thrombosis other than PE and DVT (single), and (e) other multiple VTE diagnoses. Other thrombosis events included cerebral sinus venous thrombosis, jugular venous thrombosis, portal venous thrombosis, superficial venous thrombosis, Budd Chiari syndrome, and extrahepatic portal vein obstruction.

Statistical Analysis

Participant data was downloaded from the registry site³⁸ as an Excel file for use in RStudio.⁴⁰ Continuous variables were presented as mean, standard deviation, and categorical variables as frequencies and percentages. LOS was categorized based on age and gender. Based on earlier studies, age was classified as >13, 13 to 17, 18 to 30, 31 to 50, and >50.⁴¹ A line graph and student t-test were used to find the mean difference between gender and hospital LOS. Age, sex, previous history of VTE, communicable diseases, non-communicable diseases, anticoagulant use, injury, and surgeries were included as covariates based on a priori studies.^16
-28 Multilinear regression was performed to understand whether the hospital LOS was associated with different VTE conditions such as DVT, PE, forms of thrombosis other than PE and DVT, and all VTE diagnoses. The regression model did not include other VTE diagnoses and PE + DVT due to lack of power. All independent variables, such as age, sex, previous history of VTE, communicable diseases, non-communicable diseases, anticoagulant use, injury, and surgeries, were mutually adjusted. A 2-sided P-value of <.05 was considered statistically significant.

Results

Baseline Characteristics

The mean age of the participants from the total registry data and subgroup included in this study was about 42 years. The median age of the selected group was ~41 years. Out of 633 participants diagnosed with VTE, 43.1% were older than 50 years, 37.1% were 31 to 50 years old, 22.2% were 18 to 30 years old, 5.3% were less than 13 years of age, and 1.1% were aged 13 to 17 years old. The mean hospital LOS was also similar in both total registry data and a subgroup of participants (~14 days) ranging from 1 to 151 days. Out of the subset of participants included in this study (n = 633), 55% were males, 45% were females, most of the participants were homemakers (28.9%), and about 51% were from the urban locality. Regarding comorbidity, 3.6%, and 34.5% responded to having at least one of the communicable and non-communicable diseases, respectively. As such, 2.5% responded to having COVID-19, 1.4% had TB, 0.5% had HIV, and 0.2% had dengue fever. For non-communicable diseases, 17.7% responded to having hypertension, 10.3% had renal diseases, 7.1% had liver disease, 6.6% had cancer, 2.1% had spleen disorder, 0.8% each had stroke and cardiomyopathy, 0.6% had varicose veins, and 0.2% each had congestive cardiac failure, heart failure, cor pulmonated, rheumatic heart disease, and myocarditis. In terms of other factors that might be associated with hospital LOS, 73.3% were administered anticoagulants during hospitalization, 7.9% had an injury, and 11.1% of the participants responded to having had major surgery (Table 1).

Table 1.

Baseline Characteristics.

	Total (N = 943)	Data for analysis (N = 633)
Variables	n (%) or Mean ± SD (range)	n (%) or Mean ± SD (range)
Age	42.05 ± 17.89 (0-91)	42.38 ± 18.08 (0-91)
Hospital length of stay	13.17 ± 14.55 (0-157)	13.87 ± 14.01 (1-151)
Sex
Males	511 (54.0)	348 (55.0)
Females	432 (46.0)	285 (45)
Occupation
Professional	53 (5.6)	34 (5.4)
Semi-professional	60 (6.4)	47 (7.4)
Clerical/shop/farm	43 (4.6)	24 (3.8)
Semiskilled worker	117 (12.4)	82 (13.0)
Unskilled worker	164 (17.4)	96 (15.1)
Unemployed	131 (13.9)	90 (14.2)
Student	74 (7.8)	48 (7.6)
Homemakers	265 (28.1)	183 (28.9)
Others	36 (3.8)	29 (4.5)
Locality
Rural	426 (45.2)	304 (48.0)
Urban	516 (54.7)	328 (51.8)
Communicable diseases	39 (4.1)	23 (3.6)
COVID-19	24 (2.5)	16 (2.5)
TB	17 (1.8)	9 (1.4)
Dengue	3 (0.3)	1 (0.2)
HIV	3 (0.3)	3 (0.5)
Non-communicable diseases	403 (42.7)	219 (34.59)
Hypertension	162 (17.1)	112 (17.7)
Renal diseases	94 (9.9)	65 (10.3)
Liver disease	70 (7.4)	45 (7.1)
Cancer	64 (6.7)	42 (6.6)
COPD	25 (2.6)	17 (2.7)
Spleen disorder	21 (2.2)	13 (2.1)
Ischemic heart disease	11 (1.1)	8 (1.3)
Stroke	9 (0.9)	5 (0.8)
Cardiomyopathy	8 (0.8)	5 (0.8)
Varicose veins	8 (0.8)	4 (0.6)
CCF	6 (0.6)	1 (0.2)
Heart failure	4 (0.4)	1 (0.2)
Cor pulmonate	3 (0.3)	1 (0.2)
RHD	1 (0.1)	1 (0.2)
Myocarditis	1 (0.1)	1 (0.2)
Injury	77 (8.1)	50 (7.9)
Surgery	95 (10.1)	70 (11.1)
Previous history of VTE	73 (7.7)	45 (7.1)
Anticoagulant use	691 (73.2)	464 (73.3)

Hospital LOS

Mean duration of hospital LOS among participants with different VTE diagnoses indicated that males with other forms of thrombosis other than PE and DVT had a higher hospital LOS at about 17 days. In contrast, among females, those with PE diagnosis had a longer hospital stay with an average of ~17 days. A significant difference (P < .01) between males and females was observed among participants with DVT but not others (Figure 2).

Figure 2.

Mean length of hospital stay between different VTE status and gender.

The duration of hospital LOS among different age groups indicated that ages less than 13 years had the longest mean LOS of 22 days ranging from 1 to 64 days, followed by 13 to 17 years (18 days ranging from 3 to 68 days), 18 to 30 years (~16 days ranging from 1 to 85 days), 31 to 50 years (~14 days ranging from 1 to 151 days), and older than 50 years (~12 days ranging from 1 to 62 days) (Table 2). We did not analyze the association between age categories and hospital LOS due to a lack of power with ages less than 18.

Table 2.

Frequency of Ages and Mean Hospital Length Among Different Age Groups (N = 633).

Ages	n (%)	Mean ± SD (range)
<13	34 (5.3)	22.26 ± 14.89 (1-64)
13-17	7 (1.1)	18.43 ± 22.91(3-68)
18-30	141 (22.2)	15.52 ± 15.25 (1-85)
31-50	235 (37.1)	13.51 ± 15.47 (1-151)
>50	216 (43.1)	11.71 ± 9.44 (1-62)

Multilinear regression was used to analyze hospital LOS (Table 3). After controlling for independent variables such as previous history of VTE, communicable diseases, non-communicable diseases, anticoagulant use, injury, and surgery, the model indicated that among participants who were diagnosed with DVT, age (β = −.09, P < .05) was negatively associated with hospital LOS. In addition, sex (β = 3.21, P < .05) and non-communicable disease (β = 3.51, P < .05) were significantly associated with hospital LOS among DVT participants. Interestingly, participants with longer LOS and with at least one of the VTE diagnoses were significantly associated with age (β = −.12, P < .001) and anticoagulant use (β = −2.49, P < .05). We also included the most common non-communicable disease (ie, hypertension) in a separate model controlling for all the independent variables. We found that hypertension (β = 4.16, P < .05) was independently associated with hospital LOS among DVT cases.

Table 3.

Multilinear Regression of LOS Among VTE Diagnosis.

	DVT (n = 269)		PE (n = 89)		Single VTE other than PE and DVT (n = 201)		All VTE diagnosis (n = 633)
Variables	β (S.E)	P-value	β (S.E)	P-value	β (S.E)	P-value	β (S.E)	P-value
Age	−.09 (0.04)	.046	−.19 (.0.09)	.051	−.09 (0.06)	.150	−.11 (0.03)	<.001
Sex^a	3.21 (1.49)	.032	3.97 (3.57)	.268	−2.85 (2.33)	.223	1.45 (1.10)	.190
Previous history of VTE	−1.55 (2.76)	.574	4.30 (6.21)	.491	−8.33 (4.82)	.085	−2.40 (2.14)	.264
Communicable disease	.17 (3.31)	.957	2.48 (7.05)	.725	−.72 (5.83)	.900	2.45 (2.59)	.344
Non-communicable disease	3.59 (1.62)	.043	2.09 (3.68)	.571	−2.06 (2.39)	.390	2.05 (1.14)	.072
Anticoagulant use	−3.59 (2.01)	.075	−.30 (4.08)	.940	−2.41 (2.32)	.300	−2.49 (1.26)	.048
Injury	−.02 (2.88)	.994	1.32 (5.70)	.871	−7.83 (5.04)	.121	−2.31 (2.06)	.263
Surgery	1.96 (2.47)	.427	−7.58 (6.01)	.210	.47 (3.69)	.898	1.08 (1.77)	.543

Abbreviations: DVT, deep vein thrombosis; LOS, length of hospital stay; PE, pulmonary embolism; VTE, venous thromboembolism.

Reference male; Bold values indicate significant values at p<0.05; All variables are mutually adjusted.

Discussion

It is important to highlight hospital LOS among VTE as multiple studies indicate that patients with longer hospital LOS have an increased risk of medical complications and functional decline.^31,32 In the present study, after controlling for hospital characteristics, among DVT participants, younger age was independently and significantly associated with longer hospital stays. In addition, female participants and those who responded to having at least one non-communicable disease were significantly and positively associated with longer hospital LOS. Anticoagulant use was independently associated with prolonged hospital LOS among overall VTE diagnoses. Other VTE diagnoses such as PE and forms of thrombosis other than PE and DVT, were not associated with hospital LOS.

Our study indicated that the mean age of the population was approximately 42 years, with the median age being 41 years, and the mean hospital LOS was about 14 days. Interestingly, the mean age was lower than in most studies focused on the adult population, which typically has mean ages over 60 years.^35,42
-45 Contrary to studies that indicate an increase in the risk of VTE with age,^46
-48 the present study found a different age distribution with VTE commonly diagnosed among younger age groups, particularly ages 19 to 38. This pattern aligns with studies on trauma patients in Houston (USA), which indicated that the median age of the study population was 34 years, and the greatest risk of VTE and highest likelihood of hypercoagulable maximal amplitude was among adults 31 to 50 years (P = .009 and P < .001, respectively).⁴¹ Regarding gender, a balanced distribution was observed with 55% males and 45% females, consistent with existing literature.^31,35,42,43 In terms of comorbidities, hypertension was the most reported comorbidity, followed by cancer, liver disease, renal disease, and chronic respiratory disease. This trend was consistent with findings from other studies. For instance, in a study from the Alberta-Venous Thromboembolism (AB-VTE) database, hypertension (admitted: 32.5% vs non-admitted: 14.8%; P < .001) was the most common comorbidity among venous thromboembolism patients, followed by malignancy (24.7% vs and 13.4%; P < .001) and chronic obstructive pulmonary disease (19.1% vs 8.3%; P < .001).³⁵ Other studies from the ESPHERIA registry and Jordan also indicate a similar trend.^42,44 This finding highlights the complex clinical profile of VTE patients, characterized by a diverse range of underlying health conditions.

In exploring the factors associated with hospital LOS, gender and age differences were evident. As such, a significantly longer duration of hospital stay was observed among females with DVT and among DVT participants who were less than 18 years old. Interestingly, the youngest age group in our population (0-18) exhibited the longest mean hospital stay across different VTE diagnoses such as DVT, PE, forms of thrombosis other than PE or DVT, and overall VTE diagnosis. Findings from the National Inpatient Sample in the US indicated that among adult VTE patients when stratified by type of VTE event, women with lower extremity DVT and PE had a significantly longer hospital LOS (mean ratio 1.04, P < .001) in the unadjusted model however when the model was adjusted for age, race, insurance status, hospital division, and medical comorbidities, the findings was no longer significant.⁴⁹

Multilinear regression analysis further elucidated the factors influencing hospital LOS among participants with VTE. Younger age was independently associated with longer hospital LOS among participants with VTE diagnoses, particularly among participants with DVT. This finding is interesting as most studies indicate a reverse trend with longer hospital LOS among older patients.^27,50,51 Interestingly, studies from the RIETE registry database observed that the hospital LOS was slightly lower in elderly patients despite their comorbidities and poorer prognosis. However, the age group included in the study was ≥70 years and <70 years, which is a wide age range.⁵² Many factors might influence longer hospital stays among younger patients such as underlying medical conditions, difficulty or delays in diagnosis, treatment challenges, and access to care.⁵³ Moreover, there has been less research focused on pediatric VTE compared to adult VTE as it is less common in pediatric patients leading to a lack of evidence-based guidelines for management in this population. The management of VTE in pediatric patients also differs in terms of weight-based dosing of anticoagulants and the need for careful monitoring may lengthen the hospital stay.^54,55 Future studies, including follow-up data, would be important to find the association between longer hospital LOS and younger age.

The presence of non-communicable disease was also positively associated with hospital LOS among participants with DVT, which is in line with other studies.⁴² For instance, a study from the United States reported hypertension (r = .27, P = .037) to be associated with longer hospital LOS among VTE patients.⁵⁶ Our study also reiterated these findings, as hypertension was found to be significantly and positively associated with hospital LOS. The association between hypertension and hospital LOS among participants with DVT could be partially explained by the complex interplay between renin-angiotensin and kallikrein-kinin systems interacting at several levels to modulate coagulation, fibrinolysis, and vasodilatation influencing the occurrence of thrombotic complications.⁵⁷

Our study has several limitations, such as the presence of confounding factors that could affect the external validity and the inability to stratify the age group to assess the association between different VTE diagnoses with hospital LOS due to the lack of power. Causation could not be established here as this was a cross-sectional study. Despite these limitations, our findings are of interest. It is one of the first real-time ongoing VTE national registries in India that collects hospital-based data on VTE patients, including socio-demographic, diagnostic, treatment and management, and participants’ outcomes. Moreover, our study included other forms of VTE including cerebral sinus venous thrombosis, jugular venous thrombosis, portal venous thrombosis, superficial venous thrombosis, Budd Chiari syndrome, and extrahepatic portal vein obstruction which are important VTE diagnosis but often not presented in studies. The registry also includes follow-up studies, which are not included in our study due to limited data but would be an important addition to future studies.

Conclusion

The findings provide insights into the factors influencing hospital LOS among participants with different types of VTE, highlighting the importance of age and comorbidities in predicting the hospital LOS. In our study, most of the VTE cases were males. However, the gender distribution was not very different; it was most common among homemakers, those older than 50 years, and those who lived in urban areas. The study demonstrated that the mean hospital LOS was about 14 days. The most common comorbidity was hypertension, which has been associated with longer hospital LOS in multiple studies. More interestingly, among DVT cases, longer hospital LOS was associated with younger participants, being female, and those with non-communicable diseases. Future studies with follow-up data on the younger population would be beneficial in ascertaining whether there is a causal relationship between these identified factors. Moreover, additional studies about factors associated with longer hospital stays among younger patients with VTE can help come up with age appropriate health education policies and guidelines.

Footnotes

Acknowledgements

The authors would like to thank all the respondents for participating in this study, and the Indian Council of Medical Research, New Delhi for providing the necessary financial assistance.

Ethics

Written informed consent was obtained from all participants. The study protocol was approved by the Institutional Ethics Committee (IEC), Indian Council of Medical Research - Central Ethics Committee on Human Research (File No. NCDIR/BEU/ICMR-CECHR/75/2020). Each participating site obtained ethical approval from their respective IECs.

Contributors

PR, HT, and SA conceived and designed the idea. HT and SA overall supervision, resource acquisition, project administration, review, editing, and proofreading of the manuscript. i-RegVed Team data collection and reviewing the manuscript. PR was involved in writing the original draft of the manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Indian Council of Medical Research, New Delhi (Grant No. i-RegVed/Site10/BMS-2022).

ORCID iDs

Sumit Aggarwal

Peteneinuo Rulu

References

Raskob

Angchaisuksiri

Blanco

, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363-2371. doi:10.1161/ATVBAHA.114.304488

Wang

Yap

Goto

, et al. The diagnosis and treatment of venous thromboembolism in Asian patients. Thromb J. 2018;16:4. doi:10.1186/s12959-017-0155-z

Jang

Bang

, et al. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011;9(1):85-91. doi:10.1111/j.1538-7836.2010.04108.x

Lee

Gallus

Jindal

Wang

CC.

Incidence of venous thromboembolism in Asian populations: a systematic review. Thromb Haemost. 2017;117(12):2243-2260. doi:10.1160/TH17-02-0134

Kishimoto

Lim

Tokuda

, et al. Prevalence of venous thromboembolism at a teaching hospital in Okinawa, Japan. Thromb Haemost. 2005;93(5):876-879. doi:10.1160/TH04-08-0508

Pawar

Ayyappan

Jagan

Rajendra

Mathur

Raju

Analysis of patients with venous thromboembolism in a multi-specialty tertiary hospital in South India. Indian J Vasc Endovasc Surg. 2020;7(1):29-33. doi:10.4103/ijves.ijves_31_19

Mannucci

PM.

Venous thrombosis: the history of knowledge. Pathophysiol Haemost Thromb. 2022;32(5-6):209-212. doi:10.1159/000073567

Haller

First Lines of Physiology. Trans. Cullen

Elliot; 1786.

White

An Inquiry into the Nature and Cause of the Swelling in one or both of the Lower Extremities, which sometimes happens to Lying-in-Women. Eyres Press; 1784, [In: Anning, S.T. (1957) The historical aspects of venous thrombosis. Medical History, 1, 28-37]. 1784.

10.

Bagot

Arya

Virchow and his triad: a question of attribution. Br J Haematol. 2008;143(2):180-190. doi:10.1111/j.1365-2141.2008.07323.x

11.

Piazza

Beyond Virchow’s Triad: does cardiovascular inflammation explain the recurrent nature of venous thromboembolism?

Vasc Med. 2015;20(2):102-104.

12.

Waheed

Kudaravalli

Hotwagner

DT.

Deep Vein Thromb. Updated January 19, 2023. StatPearls. StatPearls Publishing; 2024. Accessed January 5, 2024. https://www-ncbi-nlm-nih-gov.silk.library.umass.edu/books/NBK507708/

13.

Bauersachs

RM.

Clinical presentation of deep vein thrombosis and pulmonary embolism. Best practice & research. Clin Haematol. 2012;25(3):243-251. doi:10.1016/j.beha.2012.07.004

14.

Blann

Lip

GY.

Venous thromboembolism. BMJ. 2006;332: 215-219. doi:10.1136/bmj.332.7535.215

15.

Stoeva

Kirova

Staneva

Lekova

Penev

Bakalova

Recognition of unprovoked (idiopathic) pulmonary embolism–Prospective observational study. Respir Med. 2018;135:57-61.

16.

Pollack

Schreiber

Goldhaber

, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol. 2011;57(6):700-706. doi:10.1016/j.jacc.2010.05.071

17.

Ageno

Becattini

Brighton

Selby

Kamphuisen

PW.

Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93-102. doi:10.1161/CIRCULATIONAHA.107.709204

18.

Ageno

Squizzato

Garcia

Imberti

Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost. 2006;32(7):651-658. doi:10.1055/s-2006-951293

19.

Anderson

Jr Spencer

FA.

Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):1-9. doi:10.1161/01.CIR.0000078469.07362.E6

20.

Goldhaber

SZ.

Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56(1):1-7. doi:10.1016/j.jacc.2010.01.057

21.

Dicks

Moussallem

Stanbro

Walls

Gandhi

Gray

BH.

A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J Clin Med. 2024;13(2):362. doi:10.3390/jcm13020362

22.

Chen

Shen

Cui

Antipsychotic use and risk of venous thromboembolism: a meta-analysis. Psychiatry Res. 2021;296:113691. doi:10.1016/j.psychres.2020.113691

23.

Kovačič

APM

Caprnd

Mrhar

, et al. Impact of drugs on venous thromboembolism risk in surgical patients. Eur J Clin Pharmacol. 2019;75:751-767. doi:10.1007/s00228-019-02636-x

24.

Holst

Jensen

Prescott

Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010;121(17):1896-1903. doi:10.1161/CIRCULATIONAHA.109.921460

25.

Hotoleanu

Association between obesity and venous thromboembolism. Med Pharm Rep. 2020;93(2):162. doi:10.15386/mpr-1372

26.

Khan

Tritschler

Kahn

Rodger

MA.

Venous thromboembolism. Lancet. 2021;398(10294):64-77. doi:10.1016/S0140-6736(20)32658-1

27.

Lutsey

Zakai

NA.

Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20(4):248-262. doi:10.1038/s41569-022-00787-6

28.

Zöller

Svensson

Dahlbäck

Lind-Hallden

Hallden

Elf

Genetic risk factors for venous thromboembolism. Exp Rev Hematol. 2020;13(9):971-981. doi:10.1080/17474086.2020.1804354

29.

Arshad

Bjøri

Hindberg

Isaksen

Hansen

Braekkan

SK.

Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost. 2017;15(2):295-303. doi:10.1111/jth.13587

30.

White

RH.

The epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):1-4. doi:10.1161/01.CIR.0000078468.11849.66

31.

Amin

Neuman

Lingohr-Smith

Menges

Lin

Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA. Drugs Context. 2019;8:212568. doi:10.7573/dic.212568

32.

Bjøri

Johnsen

Hansen

Brækkan

SK.

Hospitalization as a trigger for venous thromboembolism: results from a population-based case-crossover study. Thromb Res. 2019;176:115-119. doi:10.1016/j.thromres.2019.02.024

33.

Henke

Kahn

Pannucci

, et al.; American Heart Association Advocacy Coordinating Committee. Call to action to prevent venous thromboembolism in hospitalized patients: a policy statement from the American Heart Association. Circulation. 2020;141(24):e914-e931. doi:10.1161/CIR.0000000000000769

34.

NICE. Venous Thromboembolism in Over 16s: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis or Pulmonary Embolism. NICE guideline [NG89]. National Institute for Health and Care Excellence. 2018. Accessed January 5, 2024. https://www.nice.org.uk/guidance/NG89

35.

Mansour

Alotaibi

McMurtry

MS.

Trends in admission rates and in-hospital stay for venous thromboembolism. Thromb Res. 2017;156:149-154. doi:10.1016/j.thromres.2017.06.012

36.

Fanikos

Piazza

Zayaruzny

Goldhaber

SZ.

Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009;102(4):688-693. doi:10.1160/TH09-04-0266

37.

Neeman

Liu

Mishra

, et al. Trends and risk factors for venous thromboembolism among hospitalized medical patients. JAMA Netw Open. 2022;5(11):e2240373. doi:10.1001/jamanetworkopen.2022.40373

38.

i-RegVed Registry. 2022. Accessed January 5, 2024. https://iregved.icmr.org.in

39.

Tabassum

Aggarwal

Menon

, et al. Development of prospective hospital-based venous thromboembolism registry across India: a study protocol. BMJ Open. 2023;13:e066644. doi:10.1136/bmjopen-2022-066644

40.

R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2024. Accessed January 5, 2024. https://www.R-project.org/

41.

Liras

Rahbar

Harting

Holcomb

Cotton

When children become adults and adults become most hypercoagulable after trauma: an assessment of admission hypercoagulability by rapid thrombelastography and venous thromboembolic risk. J Trauma Acute Care Surg. 2016;80(5):778-782. doi:10.1097/TA.0000000000000985

42.

Amawi

Arabyat

Al-Azzam

, et al. The length of hospital stay of patients with venous thromboembolism: a cross-sectional study from Jordan. Medicina. 2023;59(4):727. doi:10.3390/medicina59040727

43.

Badreldin

Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study. J Thromb Thrombolysis. 2018;46(1):16-21. doi:10.1007/s11239-018-1661-y

44.

Jimenez

Ruiz-Artacho

Merlo

, et al. Risk profile, management, and outcomes of patients with venous thromboembolism attended in Spanish emergency departments: the ESPHERIA registry. Medicine. 2017;96(48):e8796. doi:10.1097/MD.0000000000008796

45.

Salomon

Dasa

Krause

Hall

Chapple

AG.

Hospital length of stay is associated with increased likelihood for venous thromboembolism after total joint arthroplasty. Arthroplast Today. 2021;8:254-257. doi:10.1016/j.artd.2020.12.025

46.

Silverstein

Heit

Mohr

Petterson

O’Fallon

Melton

LJ.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585-593. doi:10.1001/archinte.158.6.585

47.

Tagalakis

Patenaude

Kahn

Suissa

Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(9):832.e13. doi:10.1016/j.amjmed.2013.02.024

48.

Raptis

Gourgoulianis

Daniil

Malli

Time trends for pulmonary embolism incidence in Greece. Thromb J. 2020;18:1-9. doi:10.1186/s12959-020-0215-7

49.

Marshall

Bartley

Ashrani

, et al. Sex-based disparities in venous thromboembolism outcomes: a National Inpatient Sample (NIS)-based analysis. Vasc Med. 2017;22(2), 121-127. doi:10.1177/1358863X17693103

50.

Barisonzo

Wiedermann

Unterhuber

Wiedermann

CJ.

Length of stay as risk factor for inappropriate hospital days: interaction with patient age and co-morbidity. J Eval Clin Pract. 2013;19(1):80-85. doi:10.1111/j.1365-2753.2011.01775.x

51.

Gregson

Kaptoge

Bolton

, et al.; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4(2):163-173. doi:10.1001/jamacardio.2018.4537

52.

Ortega

Jiménez

Pedro-Tudela

, et al. Age-related differences in the presentation, management, and clinical outcomes of 100,000 patients with venous thromboembolism in the RIETE registry. Arch Bronconeumol. 2024;60(3):143-152. doi:10.1016/j.arbres.2023.12.016

53.

Lassandro

Palmieri

Palladino

Amoruso

Faienza

Giordano

Venous thromboembolism in children: from diagnosis to management. Int J Environ Res Public Health. 2020;17(14):4993. doi:10.3390/ijerph17144993

54.

Male

Lensing

Palumbo

, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18-e27. doi:10.1016/S2352-3026(19)30219-4

55.

Witmer

Raffini

Treatment of venous thromboembolism in pediatric patients. Blood. 2020;135(5):335-343.

56.

Boupapanh

Infosino

Zhang

Shank

Evaluation of comorbidities and biomarkers to predict hospital length-of-stay and mortality in VTE patients. South Med J. 2022;115(1):63-64.

57.

Dielis

Smid

Spronk

, et al. The prothrombotic paradox of hypertension: Role of the renin-angiotensin and kallikrein-kinin systems. Hypertension. 2005;46(6):1236-1242. doi:10.1161/01.HYP.0000193538.20705.23

Factors Associated with Hospital Length of Stay among VTE Cases: Insights from the i-RegVed Registry

Abstract

Introduction:

Methods:

Results:

Conclusion:

Keywords

Introduction

Methods

Study Setting

Study Data Variables

Inclusion Criteria

Exclusion Criteria

Data Collection

Statistical Analysis

Results

Baseline Characteristics

Hospital LOS

Discussion

Conclusion

Footnotes

Acknowledgements

Ethics

Contributors

Declaration of Conflicting Interests

Funding

ORCID iDs

References